DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oxycodone and Aspirin (Oxycodone Hydrochloride / Oxycodone Terephthalate / Aspirin) - Summary



Each oxycodone and aspirin tablet contains: Oxycodone Hydrochloride, USP 4.

Oxycodone and aspirin tablets are indicated for the management of moderate to moderately severe pain.

See all Oxycodone and Aspirin indications & dosage >>


Media Articles Related to Oxycodone and Aspirin (Oxycodone / Oxycodone / Aspirin)

Cardiac Sonographers Extra Prone to Back, Neck, Wrist Pain
Source: Medscape Radiology Headlines [2015.11.27]
Staff in the echo lab were even more likely to have work-related musculoskeletal pain than technicians in the cath lab, in a new study.
Heartwire from Medscape

Reducing pain intensity may be the wrong treatment goal
Source: Pain / Anesthetics News From Medical News Today [2015.11.26]
Chronic Pain Treatment should focus on improving function and quality of life.It would seem intuitive that reducing pain intensity should be the primary goal of treatment for chronic pain.

Mindfulness Meditation 'Better Than Placebo' for Pain Relief
Source: Medscape NeurologyHeadlines [2015.11.25]
Pain relief through mindfulness meditation not only is significantly greater than that achieved by placebo but also utilizes different neural mechanisms, say US researchers.
Medscape Medical News

New pain mechanisms revealed for neurotoxin in spinal cord injury
Source: Neurology / Neuroscience News From Medical News Today [2015.11.25]
A toxin released by the body in response to spinal cord injuries increases pain by causing a proliferation of channels containing pain sensors, new research shows, and this hypersensitivity also...

FDA Advisors Paint Bleak Picture for DMD Drug
Source: MedPage Today Neurology [2015.11.24]
(MedPage Today) -- Evidence of efficacy for drisapersen is weak, panelists say

more news >>

Published Studies Related to Oxycodone and Aspirin (Oxycodone / Oxycodone / Aspirin)

Oxycodone-related side effects: impact on degree of bother, adherence, pain relief, satisfaction, and quality of life. [2011.05]
OBJECTIVES: Oxycodone immediate-release, alone or in combination (hereafter, oxycodone), is widely used to treat pain and is often associated with bothersome side effects. The objective was to assess side effect frequency, degree of bother, and impact on health-related quality of life (HRQoL)... CONCLUSIONS: The majority of survey respondents experienced side effects of oxycodone, with a majority being bothered by side effects and impacting their QoL. This raises a question about the unmet need for pain medications with improved side effect profiles.

Oxycodone combinations for pain relief. [2010.06]
No single analgesic drug provides the perfect therapeutic/adverse effect profile for every pain condition. In addition to convenience and possibly improved compliance, a combination of analgesic drugs offers the potential, requiring verification, of providing greater pain relief and/or reduced adverse effects than the constituent drugs when used individually...

more studies >>

Clinical Trials Related to Oxycodone and Aspirin (Oxycodone / Oxycodone / Aspirin)

Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia [Not yet recruiting]
Cystectomy with urinary diversion (ileal conduit, ileal orthotopic neobladder, catheterizable ileal pouch) is major abdominal surgery, which is associated with a high incidence of gastrointestinal complications. Perioperative techniques aiming at an early return of bowel function are to be pursued. Optimal postoperative pain management is one of the key factors leading to enhanced recovery after surgery. The perioperative use of an epidural analgesia for major abdominal surgery is established, not only because of its excellent analgesic properties, but also because it can accelerate the return of bowel function. However, epidural analgesia is associated with additional costs, need for close monitoring and nursing. In addition each supplemental day with an indwelling epidural catheter increases the risk of infection. So it is recommended to re-assess the risk/benefit ratio of an epidural analgesia after 4 days, if not sooner. Therefore, it is important to develop strategies that reduce its duration without impairing the benefits. Systemic analgesics with prolonged-release oral formulation like oral oxycodone (Oxycontin®) or combined drug mixture (oral oxycodone/naloxone (Targin®)) could be a valuable alternative pain treatment as a second analgesic step, starting on postoperative day (POD) 3, so that the epidural catheter could be removed earlier without impairing postoperative enhanced recovery including return of the bowel function. Both oxycodone and naloxone orally administered are a recognized and accepted treatment option. The objective of this study is to evaluate the implementation of an oral opioid with or without naloxone in the early postoperative period in patients undergoing open radical cystectomy with urinary diversion and intraoperative and early postoperative use of epidural analgesia. The investigators expect an unchanged early return of the bowel function and equal analgesia with a reduced length of stay of the epidural catheter (primary endpoint), thus potentially reducing epidural catheter associated complications and lowering costs (nursing and pain service).

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone [Completed]

Abuse Liability of Controlled-Release Oxycodone Formulations [Completed]
The objective of this study is to examine the abuse liability of a single 40mg dose of 2 controlled release oxycodone formulations (Apo-Oxycodone CR® and OxyNEO®) in non-dependent recreational opioid users by assessing the self-reported acute effects of the drugs and taking blood samples to measure drug concentrations. The investigators think there may be differences in how well these drugs are liked when swallowed whole due to differences in how the products are formulated.

Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain [Completed]
The efficacy of codeine is dependent on its demethylation to morphine. This extent of demethylation has wide inter-individual variability, making codeine's efficacy as a analgesic variable. Oxycodone is a semi-synthetic opioid and is a weak agonist on mu opioid receptors. Codeine has been the mainstay of analgesia for patients after craniotomy for many years. Traditionally, craniotomies were not thought to be very painful procedures, hence the use of codeine, a moderately potent opioid (when compared to morphine). However, in recent years, it has been found that up to 70% of post-craniotomy patients have moderate to severe pain and codeine did not provide adequate analgesic relief. Many studies have compared codeine to other drugs such as PCA morphine, fentanyl and tramadol, and patients on these stronger opioids generally had lower pain scores and better satisfaction. No study has been conducted to determine the efficacy of analgesia of oral oxycodone to oral codeine. Hence, the hypothesis is that oxycodone is more effective than codeine in providing pain relief in post-craniotomy patients.

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans [Completed]
Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is potential for off label use in chronic pain. Tapentadol is a new molecular entity that is structurally similar to tramadol. Tapentadol is a centrally-acting analgesic with a dual mode of action as an agonist at the mu-opioid receptor and as a norepinephrine reuptake inhibitor. These two actions are synergistic in pain relief. While its action reflects aspects of tramadol and morphine, its ability to control pain is more on the order of hydrocodone and oxycodone. Its dual mode of action provides analgesia at similar levels of more potent narcotic analgesics such as hydrocodone, oxycodone, and meperidine with a more tolerable side effect profile. Clinical studies showed that tapentadol effectively relieves moderate to severe pain in various pain care settings. In addition, it was reported to be associated with significantly fewer treatment discontinuations due to a significantly lower incidence of gastrointestinal-related adverse events compared with equivalent doses of oxycodone. The combination of these reduced treatment discontinuation rates and tapentadol efficacy for the relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in pain therapy by increasing patient compliance with their treatment regimen.

more trials >>

Page last updated: 2015-11-27

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015